Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | STAT3 | P40763 | 4/20 | 0.39 |
| ▸ | PDE6D | O43924 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617071 | 0.89 | CRBN (0.61) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL24459075 | 0.89 | CRBN (0.61) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL29085676 | 0.88 | CRBN (0.59) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL28989025 | 0.87 | CRBN (0.58) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL24458962 | 0.86 | CRBN (0.59) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL25346527 | 0.86 | CRBN (0.54) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL31288838 | 0.85 | CRBN (0.55) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL29085660 | 0.84 | CRBN (0.54) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL24459097 | 0.84 | CRBN (0.57) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL31288860 | 0.84 | CRBN (0.52) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743069-B1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BIOVENTURES, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| EP-3743069-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BioVentures, LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019144117-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES, LLC (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BCL2, BCL2L1, BCL2L2 | CRBN 263/4885DDB1 163/4885TNF 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.